Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Livingwell Medical Center accepts most major insurance plans but also offers affordable self-pay rates for patients without ...

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

The combination met its primary endpoint of percent weight loss following an 8-week treatment period.

Eli Lilly’s direct-to-consumer service added knownwell to its line-up of providers who can prescribe its medications, as it ...

The study concluded that treatment with SGLT-2I in conjunction with GLP-1RA may help to reduce the incidence of AF/flutter ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutideStudy will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2 ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...